356 related articles for article (PubMed ID: 22770575)
1. Fixed topical combinations in glaucomatous patients and ocular discomfort.
Nebbioso M; Evangelista M; Librando A; Di Blasio D; Pescosolido N
Expert Opin Pharmacother; 2012 Sep; 13(13):1829-35. PubMed ID: 22770575
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Sezgin Akçay Bİ; Güney E; Bozkurt KT; Unlü C; Akçali G
J Ocul Pharmacol Ther; 2013 Dec; 29(10):882-6. PubMed ID: 24180628
[TBL] [Abstract][Full Text] [Related]
3. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Michaud JE; Friren B;
Am J Ophthalmol; 2001 Aug; 132(2):235-43. PubMed ID: 11476685
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Manni G; Denis P; Chew P; Sharpe ED; Orengo-Nania S; Coote MA; Laganovska G; Volksone L; Zeyen T; Filatori I; James J; Aung T
J Glaucoma; 2009; 18(4):293-300. PubMed ID: 19365194
[TBL] [Abstract][Full Text] [Related]
5. [Azarga, a new and useful fixed combination in glaucoma treatment].
Călugăru M; Călugăru D
Oftalmologia; 2011; 55(3):38-46. PubMed ID: 22428291
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients.
Renieri G; Führer K; Scheithe K; Lorenz K; Pfeiffer N; Thieme H
J Ocul Pharmacol Ther; 2010 Dec; 26(6):597-603. PubMed ID: 20977366
[TBL] [Abstract][Full Text] [Related]
7. Brinzolamide/timolol fixed combination: a new ocular suspension for the treatment of open-angle glaucoma and ocular hypertension.
Holló G; Bozkurt B; Irkec M
Expert Opin Pharmacother; 2009 Aug; 10(12):2015-24. PubMed ID: 19618994
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
[TBL] [Abstract][Full Text] [Related]
9. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension.
Vold SD; Evans RM; Stewart RH; Walters T; Mallick S
J Ocul Pharmacol Ther; 2008 Dec; 24(6):601-5. PubMed ID: 19049301
[TBL] [Abstract][Full Text] [Related]
10. Signs and symptoms of ocular surface status in glaucoma patients switched from timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month efficacy and tolerability, multicenter, open-label prospective study.
Rossi GC; Tinelli C; Pasinetti GM; Fusetti M; Pallavicini C; Stringa M; Vacchi S; Stringa F; Bianchi PE
Expert Opin Pharmacother; 2011 Apr; 12(5):685-90. PubMed ID: 21385109
[TBL] [Abstract][Full Text] [Related]
11. Brinzolamide/timolol versus dorzolamide/timolol fixed combinations: A hospital-based, prospective, randomized study.
Galose MS; Elsaied HM; Macky TA; Fouad PH
Indian J Ophthalmol; 2016 Feb; 64(2):127-31. PubMed ID: 27050347
[TBL] [Abstract][Full Text] [Related]
12. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group.
Silver LH
Surv Ophthalmol; 2000 Jan; 44 Suppl 2():S141-5. PubMed ID: 10665516
[TBL] [Abstract][Full Text] [Related]
13. From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch study.
Rossi GC; Pasinetti GM; Sandolo F; Bordin M; Bianchi PE
Expert Opin Pharmacother; 2011 Nov; 12(16):2425-31. PubMed ID: 21679090
[TBL] [Abstract][Full Text] [Related]
14. Predictors for visual field progression and the effects of treatment with dorzolamide 2% or brinzolamide 1% each added to timolol 0.5% in primary open-angle glaucoma.
Martínez A; Sanchez-Salorio M
Acta Ophthalmol; 2010 Aug; 88(5):541-52. PubMed ID: 19799592
[TBL] [Abstract][Full Text] [Related]
15. Topical carbonic anhydrase inhibitors and visual function in glaucoma and ocular hypertension.
Gugleta K
Curr Med Res Opin; 2010 Jun; 26(6):1255-67. PubMed ID: 20350146
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide.
Clineschmidt CM; Williams RD; Snyder E; Adamsons IA
Ophthalmology; 1999 Dec; 106(12 Suppl):17-24. PubMed ID: 10598693
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma.
Konstas AG; Kozobolis VP; Tersis I; Leech J; Stewart WC
Eye (Lond); 2003 Jan; 17(1):41-6. PubMed ID: 12579169
[TBL] [Abstract][Full Text] [Related]
18. Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group.
Adamsons IA; Polis A; Ostrov CS; Boyle JE
J Glaucoma; 1998 Dec; 7(6):395-401. PubMed ID: 9871861
[TBL] [Abstract][Full Text] [Related]
19. Brinzolamide/timolol: in open-angle glaucoma and ocular hypertension.
Croxtall JD; Scott LJ
Drugs Aging; 2009; 26(5):437-46. PubMed ID: 19552495
[TBL] [Abstract][Full Text] [Related]
20. Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects.
Stewart WC; Day DG; Stewart JA; Holmes KT; Jenkins JN
Eye (Lond); 2004 Sep; 18(9):905-10. PubMed ID: 15002017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
